Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Foamix Pharmaceuticals Ltd.FOMX · Entity 150527 | VP Innovation & Discovery | February 27, 2018 | February 28, 2018 |
| Silexion Therapeutics CorpSLXN · Entity 8506 | CSO and CDO | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Foamix Pharmaceuticals Ltd.
Report date February 27, 2018 · Filed February 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 24,980 |
Reported balance
After 2018-02-27 transaction · row 1
1 source rowRow 1 · 2018-02-27 · Grant · Acquired 5,000 · Balance 24,980 F2: The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. F1: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2028-02-27 | Direct | 15,000 |
Reported balance
After 2018-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-02-27 · Grant · Acquired 15,000 · Balance 15,000 F3: Each option represents a contingent right to purchase one ordinary share of the issuer. F4: The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
F2: The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.
F3: Each option represents a contingent right to purchase one ordinary share of the issuer.
F4: The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022.
Silexion Therapeutics Corp
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 8,789 |
Reported balance
After 2026-06-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 6,000 · Balance 8,789 F1: The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the last Form 4 filed by the Reporting Person on March 30, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 27,889 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 2,789 ordinary shares, par value $0.135, prior to the grant reported in this Form 4). F2: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors. |
| Stock Option (right to buy Ordinary Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $9,077.10 · Expires 2032-06-07 | Direct | 48 |
Reported balance
Holding disclosure · report date 2026-06-04 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 48 F3: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. F4: The number of options to purchase ordinary shares, underlying ordinary shares, and the exercise price of those options reported in this row have been adjusted to reflect the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 478 options to purchase 478 ordinary shares, par value $0.0135, at an exercise price of $907.71 per share, beneficially owned by the Reporting Person, as reported in that Form 4, to become 48 options to purchase 48 ordinary shares, par value $0.135, at an exercise price of $9,077.10 per share). |
Filing footnotes · ownership attribution and instrument terms
F1: The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the last Form 4 filed by the Reporting Person on March 30, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 27,889 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 2,789 ordinary shares, par value $0.135, prior to the grant reported in this Form 4).
F2: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors.
F3: There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
F4: The number of options to purchase ordinary shares, underlying ordinary shares, and the exercise price of those options reported in this row have been adjusted to reflect the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 478 options to purchase 478 ordinary shares, par value $0.0135, at an exercise price of $907.71 per share, beneficially owned by the Reporting Person, as reported in that Form 4, to become 48 options to purchase 48 ordinary shares, par value $0.135, at an exercise price of $9,077.10 per share).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 20:06 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantOrdinary Shares | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-003136 · zk2635517.xml · nonDerivative · entry 1 Shirvan Mitchell · CIK 0001727789 · CSO and CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,789 F1 · security: The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the last Form 4 filed by the Reporting Person on March 30, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 27,889 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 2,789 ordinary shares, par value $0.135, prior to the grant reported in this Form 4). F2 · kind: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors. Read SEC document |
| March 26, 2026 Filed Mar 30, 2026 21:29 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | SaleOrdinary Shares | 22,818 | $1.36 | $31,032.48 |
DisclosureSEC source: 0001178913-26-001858 · zk2634986.xml · nonDerivative · entry 1 Shirvan Mitchell · CIK 0001727789 · CSO and CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,889 F1 · kind: The transaction was a sale-to-cover to cover tax liability stemming from the Reporting Person's receipt of a grant of fully vested restricted share units on February 20, 2026, as reported in the Form 4 filed by the Reporting Person on February 23, 2026. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 21:18 UTC | Silexion Therapeutics Corp SLXN · Entity 8506 | GrantOrdinary Shares | 49,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-000604 · ownership.xml · nonDerivative · entry 1 Shirvan Mitchell · CIK 0001727789 · CSO and CDO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,707 F1 · security: The number of ordinary shares, par value $0.0135 per share ("ordinary shares"), reported in this Form 4 reflect adjustments relative to the Form 3 filed by the Reporting Person due to the 1-for 9 and 1-for-15 reverse share splits effected by the Issuer on November 29, 2024 and July 29, 2025, respectively. F2 · kind: The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 16:15 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOptions · Derivative | 15,000 | $6.40 Strike: $6.40 | $96,000.00 |
DisclosureSEC source: 0001178913-18-000730 · zk1821311.xml · derivative · entry 2 Shirvan Mitchell · CIK 0001727789 · VP Innovation & Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 15,000 shares Expires 2028-02-27 F3 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F4 · derivative.exercise_date: The ordinary shares underlying these options vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 16:15 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOrdinary Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-18-000730 · zk1821311.xml · nonDerivative · entry 1 Shirvan Mitchell · CIK 0001727789 · VP Innovation & Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,980 F2 · shares: The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on February 27, 2019 and 6.25% every three months thereafter) ending February 27, 2022. F1 · price: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. Read SEC document |
| January 15, 2018 Filed Jan 24, 2018 20:29 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionRestricted Share Units · Derivative | 562 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001178913-18-000269 · a1821074.xml · derivative · entry 4 Shirvan Mitchell · CIK 0001727789 · VP Innovation & Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 562 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F4 · derivative.exercise_date: The ordinary shares underlying this restricted share unit award vest in equal installments every three months over the vesting period beginning January 15, 2018 and ending January 15, 2019. F4 · derivative.expiration_date: The ordinary shares underlying this restricted share unit award vest in equal installments every three months over the vesting period beginning January 15, 2018 and ending January 15, 2019. F5 · balance_after: This class of restricted share units is included in Column 5 of Table I above. Read SEC document |
| January 15, 2018 Filed Jan 24, 2018 20:29 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionOrdinary Shares | 562 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-18-000269 · a1821074.xml · nonDerivative · entry 2 Shirvan Mitchell · CIK 0001727789 · VP Innovation & Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · balance_after: The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 6,184 ordinary shares previously reported in Table I of the reporting person's Form 3, (ii) 2,745 ordinary shares underlying restricted share units that vested on January 1, 2018, (iii) 562 ordinary shares underlying restricted share units that vested on January 15, 2018 and (iv) 10,489 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security. Read SEC document |
| January 01, 2018 Filed Jan 24, 2018 20:29 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionRestricted Share Units · Derivative | 2,745 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001178913-18-000269 · a1821074.xml · derivative · entry 3 Shirvan Mitchell · CIK 0001727789 · VP Innovation & Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F3 · derivative.exercise_date: The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021. F3 · derivative.expiration_date: The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021. F5 · balance_after: This class of restricted share units is included in Column 5 of Table I above. Read SEC document |
| January 01, 2018 Filed Jan 24, 2018 20:29 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Exercise / conversionOrdinary Shares | 2,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-18-000269 · a1821074.xml · nonDerivative · entry 1 Shirvan Mitchell · CIK 0001727789 · VP Innovation & Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,980 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer. F2 · balance_after: The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 6,184 ordinary shares previously reported in Table I of the reporting person's Form 3, (ii) 2,745 ordinary shares underlying restricted share units that vested on January 1, 2018, (iii) 562 ordinary shares underlying restricted share units that vested on January 15, 2018 and (iv) 10,489 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.